Canada markets closed

IBEX Technologies Inc. (IBT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.57000.0000 (0.00%)
At close: 10:55AM EDT
Full screen
Previous Close0.5700
Open0.5600
Bid0.5500 x 0
Ask0.5800 x 0
Day's Range0.5600 - 0.5700
52 Week Range0.2700 - 0.6400
Volume4,500
Avg. Volume8,954
Market Cap14.149M
Beta (5Y Monthly)0.25
PE Ratio (TTM)9.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    IBEX Technologies Announces Normal Course Issuer Bid

    MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today announced that the TSX Venture Exchange (“TSXV”) has approved IBEX’s normal course issuer bid (“NCIB”). Under the NCIB, IBEX may purchase for cancellation a maximum of 1,800,000 common shares, representing approximately 9.9% of the 18,198,067 shares forming IBEX’s public float. The shares may be purchased through the facilities of the TSXV. The NCIB will commence on August 5, 202

  • GlobeNewswire

    IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022

    MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022. “We are pleased with the continued growth in sales, driven by strong sales of heparinase-based products, as well as by the sales of aryl-acyl amidase, a product used in tests for acetaminophen poisoning; and also with the continued strengthening of the Company’s balance sheet” said Paul Baehr, IBEX P

  • GlobeNewswire

    IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2022

    MONTRÉAL, March 17, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2022. “We are pleased with the continued growth driven by strong sales of heparinase-based products,” said Paul Baehr, IBEX President & CEO “and with the continued strengthening of the Company’s balance sheet. We foresee the trend to continue for the balance of the fiscal year.” Note: All figures are in Canadian